DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)



company name or ticker
Company Photos
(Click to zoom)

Big Swings in Biotech Short Interest

Gilead Sciences, inc. Stock's Green Light Sparks Offensive

Gilead Sciences will need to convince healthcare payers to prescribe its new hepatitis C drug Harvoni.

Vertex Pharmaceuticals (VRTX) Updates on Kalydeco Studies - Analyst Blog

Stock Market News for October 09, 2014 - Market News

Why You Shouldn't Bet Against Vertex Pharmaceuticals (VRTX) Stock - Tale of the Tape

Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog

Everything you need to know about investing you learned in grade school

Vertex Pharmaceticals insiders sell 537,645 shares this month

The Most Important Number You Need to Know Before Buying Gilead Sciences Inc. Stock

Gilead's future is almost entirely dependent on Sovaldi's success. How high is the ceiling for this one-of-a-kind blockbuster drug?

HCV: The 'C' Stands For Cure

See More Articles...